Published in Biostatistics on August 25, 2010
The analysis of multivariate longitudinal data: a review. Stat Methods Med Res (2012) 1.22
Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times. Biometrics (2013) 0.77
ANALYSIS OF DEPENDENTLY CENSORED DATA BASED ON QUANTILE REGRESSION. Stat Sin (2014) 0.75
Multivariate Longitudinal Analysis with Bivariate Correlation Test. PLoS One (2016) 0.75
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology (2000) 15.40
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation (1987) 5.73
Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol (2006) 5.25
Estimation and extrapolation of optimal treatment and testing strategies. Stat Med (2008) 4.57
Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med (2008) 3.83
Causal effect models for realistic individualized treatment and intention to treat rules. Int J Biostat (2007) 2.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med (2004) 10.65
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med (2012) 8.88
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25
Comment: Demystifying Double Robustness: A Comparison of Alternative Strategies for Estimating a Population Mean from Incomplete Data. Stat Sci (2007) 6.65
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med (2008) 4.33
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Semiparametric Estimation of Treatment Effect in a Pretest-Posttest Study with Missing Data. Stat Sci (2005) 3.90
Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med (2008) 3.83
A robust method for estimating optimal treatment regimes. Biometrics (2012) 3.76
Median regression with censored cost data. Biometrics (2002) 3.34
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J (2006) 3.14
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics (2008) 3.04
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
International variation in and factors associated with hospital readmission after myocardial infarction. JAMA (2012) 2.75
A semiparametric likelihood approach to joint modeling of longitudinal and time-to-event data. Biometrics (2002) 2.74
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Improving efficiency and robustness of the doubly robust estimator for a population mean with incomplete data. Biometrika (2009) 2.61
Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation (2006) 2.60
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA (2008) 2.59
Semiparametric estimation of treatment effect in a pretest-posttest study. Biometrics (2003) 2.53
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials. Biometrics (2002) 2.50
Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol (2006) 2.40
The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol (2004) 2.34
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Conditional estimation for generalized linear models when covariates are subject-specific parameters in a mixed model for longitudinal measurements. Biometrics (2004) 2.26
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation (2008) 2.19
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet (2009) 2.13
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J (2013) 2.12
Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. Am J Med (2005) 2.08
Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials. Biometrics (2004) 2.07
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation (2013) 2.03
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol (2010) 2.00
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke (2013) 1.99
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J (2011) 1.98
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol (2005) 1.96
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. Eur Heart J (2007) 1.95
Estimating Optimal Treatment Regimes from a Classification Perspective. Stat (2012) 1.95
Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. Am J Epidemiol (2004) 1.94
Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation (2002) 1.88
Can one assess whether missing data are missing at random in medical studies? Stat Methods Med Res (2006) 1.85
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation (2012) 1.84
Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA (2009) 1.80
Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes (2010) 1.76
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J (2011) 1.72
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. J Card Fail (2006) 1.72
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med (2010) 1.70
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation (2007) 1.67
Doubly robust estimation of causal effects. Am J Epidemiol (2011) 1.66
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation (2012) 1.66
An estimator for the proportional hazards model with multiple longitudinal covariates measured with error. Biostatistics (2002) 1.63
Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J (2012) 1.59
Robust estimation of optimal dynamic treatment regimes for sequential treatment decisions. Biometrika (2013) 1.59
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Eur Heart J (2013) 1.56
Comparison between two partial likelihood approaches for the competing risks model with missing cause of failure. Lifetime Data Anal (2005) 1.54
The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. Crit Care Med (2013) 1.52
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med (2011) 1.50
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Eur Heart J (2009) 1.48
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol (2009) 1.45
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart (2013) 1.45
Gene-trait similarity regression for multimarker-based association analysis. Biometrics (2009) 1.44
"Smooth" semiparametric regression analysis for arbitrarily censored time-to-event data. Biometrics (2007) 1.41
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. Heart Rhythm (2006) 1.41